How Has the Chronic Pulmonary Hypertension Treatment Market Evolved Historically and What is its Current Size?
The chronic pulmonary hypertension treatment market has seen considerable growth due to a variety of factors.
• In recent times, the market size for chronic pulmonary hypertension treatment has seen considerable enlargement. The market, valued at $6.82 billion in 2024, is projected to ascend to $7.21 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.8%.
Factors such as a rise in the occurrence rate of chronic pulmonary hypertension, approval of more drugs, beneficial reimbursement policies, mounting healthcare costs, and an increasing elderly population have contributed to the growth during the historic period.
What is the Forecasted Market Size and CAGR for the Chronic Pulmonary Hypertension Treatment Market?
The chronic pulmonary hypertension treatment market is expected to maintain its strong growth trajectory in upcoming years.
• Growth is anticipated in the market size for chronic pulmonary hypertension treatments over the next several years. The market is predicted to expand to $8.95 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.6%.
Factors contributing to this expected growth during the forecast period include an escalating demand for competent treatments, increasing funding, government support for medicinal development, increasing demand for state-of-the-art therapeutic options, heightened awareness, and rising incidence of chronic brain trauma. Notable trends predicted for the forecast period encompass discovery of novel drugs and therapies, technological advancement, alliances with pharmaceutical conglomerates, research agencies, and healthcare entities, identification of new molecular pathways, coupled with investment from governments and healthcare organizations and innovation of new therapeutic measures.
Which Factors Are Boosting Growth In The Chronic Pulmonary Hypertension Treatment Market?
The chronic pulmonary hypertension treatment market is projected to grow due to the high incidence of cardiovascular diseases. These diseases encompass various heart and blood vessel disorders including conditions like coronary artery disease, heart failure, and stroke. High incidence of these conditions is linked to factors such as unhealthy eating habits, lack of physical exercise, tobacco usage, excessive alcohol consumption, obesity, hypertension, diabetes, and an ageing population. Treatment for chronic pulmonary hypertension contributes to cardiovascular wellbeing by reducing pulmonary artery pressure, enhancing heart functionality, and decreasing the chances of heart failure and related complications. As an example, the Australian Institute of Health and Welfare, a government agency based in Australia, reported in December 2023 that doctor-certified deaths due to coronary heart disease (CHD) increased from 14,100 in 2021 to 14,900 in 2022. Hence, the increasing prevalence of cardiovascular diseases is a driving force for the expansion of the chronic pulmonary hypertension treatment market.
What Are The Market Segments In The Chronic Pulmonary Hypertension Treatment Market?
The chronic pulmonary hypertension treatment market covered in this report is segmented –
1) By Drug Type: Endothelin Receptor Antagonists, Phosphodiesterase (PDE-5) Inhibitors, Prostacyclin Analogs, Soluble Guanylate Cyclase (SGC) Stimulators
2) By Route Of Administration: Oral, Intravenous Or Subcutaneous, Inhalational
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Endothelin Receptor Antagonists: Bosentan, Ambrisentan, Macitentan
2) By Phosphodiesterase (PDE-5) Inhibitors: Sildenafil, Tadalafil, Vardenafil
3) By Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost
4) By Soluble Guanylate Cyclase (SGC) Stimulators: Riociguat
Pre-Book The Chronic Pulmonary Hypertension Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Chronic Pulmonary Hypertension Treatment Market?
The focus of prominent players in the chronic pulmonary hypertension treatment market is on the creation of innovative solutions like subcutaneous injections. These are aimed at increasing patient adherence, facilitating convenience and offering more targeted treatment alternatives. Subcutaneous injections work by supplying continuous medication under the skin, which aids in reducing pulmonary artery pressure and enhancing blood flow in individuals with pulmonary hypertension. For example, in March 2024, Merck & Co Inc., an American pharmaceutical firm, revealed that the U.S. Food and Drug Administration (FDA) had given its approval for Winrevair (sotatercept-csrk). This marked a considerable breakthrough in the treatment of pulmonary arterial hypertension (PAH). What sets this innovative therapy apart is its unique benefits, making it a revolutionary option for PAH. In clinical tests, Winrevair showed an improvement in the WHO functional class in 29% of patients, as opposed to 14% in the placebo group, which contributes to an overall betterment in their quality of life.
Who Are the Key Players In The Chronic Pulmonary Hypertension Treatment Market?
Major companies operating in the chronic pulmonary hypertension treatment market are:
• Pfizer Inc.
• Johnson & Johnson
• Merck & Co. Inc.
• Bayer AG
• Sanofi SA
• AstraZeneca PLC
• Novartis AG
• GSK (GlaxoSmithKline)
• Eli Lilly and Company
• Amgen Inc.
• Gilead Sciences Inc.
• Boehringer Ingelheim
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Sumitomo Pharma Co. Ltd.
• Insmed
• Cereno Scientific
• Roivant Sciences
• LGM Pharma
• Liquidia Technologies
What Are The Regional Insights Into The Chronic Pulmonary Hypertension Treatment Market?
North America was the largest region in the chronic pulmonary hypertension treatment market in 2024. The regions covered in the chronic pulmonary hypertension treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
